Previous 10 | Next 10 |
Oramed Pharmaceuticals ( ORMP +8.6% ) announces that it has successfully concluded its End of Phase 2 meeting with the FDA regarding its oral insulin capsule (ORMD-0801) for type 2 diabetics. More news on: Oramed Pharmaceuticals Inc., Healthcare stocks news, Stocks on th...
NEW YORK , July 15, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that the FDA provided positive feedback during the c...
Oramed Pharmaceuticals (NASDAQ: ORMP ): Q3 GAAP EPS of -$0.10 beats by $0.10 . More news on: Oramed Pharmaceuticals Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
NEW YORK , June 15, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that its pilot study of its oral insulin candidate OR...
NEW YORK , May 5, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced it will present during the 80 th American Diabetes Ass...
NEW YORK , April 7, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Canadian Patent Office has indicated its intent t...
InflaRx N.V. IFRX +54% with doses of first COVID-19 with IFX-1. More news on: Qumu Corporation, Safe-T Group Ltd, Trxade Group, Stocks on the move, , Read more ...
NEW YORK , April 1, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, is pleased to provide the following Letter to Shareholders from Chief...
Oramed Pharmaceuticals (NASDAQ: ORMP ) perks up 7% premarket on light volume on the heels of its initial End-of-Phase 2 meeting with the FDA related to Chemistry, Manufacturing and Controls (CMC) data on oral insulin capsule ORMD-0801. More news on: Oramed Pharmaceuticals Inc...
NEW YORK , March 19, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced positive feedback from its initial End-of-Phase 2 (EoP2) ...
News, Short Squeeze, Breakout and More Instantly...
Oramed Pharmaceuticals Inc. Company Name:
ORMP Stock Symbol:
NASDAQ Market:
Oramed Pharmaceuticals Inc. Website:
PALO ALTO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today...
Crescent Energy Company Class A (CRGY) is expected to report $0.21 for Q4 2023 ThredUp Inc. (TDUP) is expected to report $-0.13 for Q4 2023 Wright Investors` Service Holdings Inc (IWSH) is expected to report for Q4 2023 Bridgford Foods Corporation (BRID) is expected to report for Q1 2...